ClinicalTrials.gg
CompletedNCT06230588Updated Jul 16, 2025

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

A Phase 1 interventional study of TQH3906 capsule and TQH3906 placebo in Psoriasis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
122nd of 182
96 · median 171
Started
2024
with 24 others
Phase 1
37 of 206
5 open now
Registered
125th of 206
by date
Lead sponsor
5 of 206
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Among the 206 studies in Psoriasis with a site in China, this one is the 122nd largest by enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 37 in phase 1, and was the 125th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This study was divided into three parts: single and multiple dosing and food effect study, which were designed to evaluate the safety and tolerability of TQH3906 capsules administered in single or multiple dose escalation in healthy adult subjects.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects aged 18-55 years (including 18 and 55 years), regardless of gender.
  • Males weighing ≥ 50 kg, females weighing ≥ 45 kg, with a (BMI) of 19-26 kg/m2 (included).
  • Be in good health with no abnormalities of clinical significance according to medical history, clinical symptoms, vital signs, physical examination, 12-lead , chest radiographs, abdominal ultrasound, and laboratory tests
  • Have a full understanding of the study, participate in the trial voluntarily, and have signed a written form.
  • Subjects (including partners) are willing to voluntarily use appropriate and effective from screening until 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating women.
  • Previous history or current cardiac, endocrine, metabolic, renal, hepatic, gastrointestinal, dermatologic, infectious, hematologic, neurologic, or psychiatric disorders/abnormalities, or related chronic illnesses, or acute illnesses, which the investigator assesses as for participation in the trial.
  • Have a > 450 ms in males and > 470 ms in females at screening, or whose Electrocardiograph () is unsuitable for Concentration QT (C-QT) measurement (at the discretion of the investigator).
  • The presence of risk factors and history of tip-twist ventricular tachycardia including, but not limited to: unexplained syncope, long QT syndrome, heart failure, or abnormal laboratory tests (including hypokalemia, hypercalcemia, or hypomagnesemia) identified at Screening.
  • Presence of abnormal serum virology at screening;

    1. Active hepatitis, or surface antigen (HBsAg) positive, or virus (HCV) antibody positive;
    2. Positive for (HIV) antibody at the screening stage, or previous history of HIV infection;
    3. Positive antibodies to Treponema pallidum in screening.
  • Presence of active tuberculosis during the Screening Period, or being a close household contact of a patient with untreated active tuberculosis, or having a positive tuberculosis interferon gamma release assay (TB-IGRA) by laboratory examination.
  • A history of severe bacterial, fungal or viral infection requiring hospitalization for intravenous antibiotic or antiviral medication within 2 months prior to randomization.
  • within 4 weeks prior to randomization or planning to receive a live vaccine during the study.
  • The presence of clinically significant infections during the Screening Period, including but not limited to upper respiratory tract infections, lower respiratory tract infections, herpes simplex, herpes zoster, and requiring treatment with antibiotics or antiviral medications.
  • A history of severe herpes zoster or herpes simplex infection including, but not limited to, herpes encephalitis, disseminated herpes simplex, and herpes zoster pandemic.
  • Use of any systemic cytotoxic or systemic drug within 6 months prior to randomization, or use of any topical cytotoxic or topical immunosuppressive drug within 4 weeks or 5 half-lives (whichever is longer) prior to randomization.
  • Receipt of a biologic or other clinical trial drug within 3 months or 5 half-lives, whichever is longer, prior to randomization.
  • Has undergone surgery within 4 weeks prior to randomization or is scheduled to undergo surgery during the study.
  • Who has lost or donated more than 400 mL of blood within 4 weeks prior to randomization.
  • Who have taken any prescription, over-the-counter, and herbal medications, except vitamin products, within 4 weeks prior to randomization.
  • Persons with potential blood collection difficulties and a history of needle and blood sickness.
  • Allergy to any of the known components of TQH3906 or any previous history of severe drug allergy.
  • History of substance abuse or positive urine drug screen.
  • Who have smoked more than 5 cigarettes/day or used an equivalent amount of nicotine or nicotine-containing products in the 3 months prior to randomization, or who are unable to discontinue the use of any tobacco-based products during the trial.
  • Those who have chronic alcohol abuse or who have consumed more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits of 40% alcohol by volume or 150 mL of wine) in the 3 months prior to screening or who are unable to abstain from alcohol for the duration of the trial, or who have a positive breath test for alcohol.
  • Have any other valid medical, psychiatric, or social reason that, in the opinion of the investigator, precludes participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    TQH3906 capsule

    TQH3906 capsule for oral administration as a single or multiple dose for 7days.

    Drug: TQH3906 capsule

  • Placebo comparator
    TQH3906 placebo capsule

    TQH3906 placebo capsule for oral administration as single dose or multiple dose for 7days.

    Drug: TQH3906 placebo

Interventions

  • TQH3906 is a kinase inhibitor.

  • DrugTQH3906 placebo

    Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Adverse events (AE)

    Incidence of adverse events (AE)

    Time frame: Up to 18 days

  2. Serious Adverse Events (SAE)

    Incidence of serious adverse events (SAE)

    Time frame: Up to 18 days

  3. Treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 18 days

Secondary outcomes

  1. Time to peak concentration (Tmax)

    The time it takes to reach the peak concentration

    Time frame: Up to 18 days

  2. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: Up to 18 days

  3. Area under the blood concentration-time curve

    The amount of drug absorbed into the circulation after administration of a single dose can be estimated from the area under the blood concentration-time curve, with Auc in units of concentration \* time.

    Time frame: Up to 18 days

  4. Apparent volume of distribution (Vd/F)

    It is the ratio of the amount of drug in the body to the blood concentration of the drug when the drug reaches dynamic equilibrium in the body is called the apparent volume of distribution.

    Time frame: Up to 18 days

  5. Plasma clearance (CL/F)

    It is the sum of drug clearance by the liver and kidneys, etc., i.e., how many volumes of plasma are cleared of drug per unit of time in L/h, or L/(kg-h) if calculated on the basis of body weight.

    Time frame: Up to 18 days

  6. Plasma elimination half-life (t1/2)

    The time required for the concentration of a drug in the blood or the amount of drug in the body to be reduced to 1/2. The time required for absorption, distribution and elimination of half the amount of drug (or blood concentration) in the body becomes the absorption half-life, distribution half-life and elimination half-life, respectively.

    Time frame: Up to 18 days

  7. Steady-state peaking time (Tmax, ss)

    The time required to reach a steady-state peak concentration after administration.

    Time frame: Up to 18 days

  8. Steady state peak concentration (Cmax, ss)

    The steady-state blood drug concentration is a serrated plasma drug concentration curve, with the highest steady-state blood drug concentration being the peak steady-state blood drug concentration.

    Time frame: Up to 18 days

  9. Steady state valley concentration (Cmin, ss)

    The steady-state blood drug concentration is a serrated plasma drug concentration curve, with the lowest steady-state blood drug concentration being the trough of the steady-state blood drug concentration.

    Time frame: Up to 18 days

  10. Average steady-state blood drug concentration (Cav, ss)

    The average concentration reached when the drug concentration reaches a steady state after a continuous given dose of medication.

    Time frame: Up to 18 days

  11. Area under steady-state blood drug concentration time curve (AUC0- τ)

    After a single dose administration, the amount of medication absorbed into the human bloodstream can be estimated using the area under the blood drug concentration time curve, with the unit of Auc being concentration \* time.

    Time frame: Up to 18 days

  12. Accumulation ratio (Rac)

    The ratio of the required dose for a single administration to the total dose required for a split administration.

    Time frame: Up to 18 days

  13. Renal clearance rate (CLr/F)

    The ability of both kidneys to completely remove a substance equivalent to several milliliters of plasma within one minute.

    Time frame: Up to 18 days

  14. INF-γ release

    Inhibition efficiency of INF-γ release by TQH3906 in IL-12/IL-18-stimulated peripheral blood mononuclear cells from subjects.

    Time frame: Up to 18 days

  15. QTcF interval

    Effect of TQH3906 on the QTcF interval in healthy subjects.

    Time frame: Up to 18 days

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 61000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2025, 14 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2024
First posted
Jan 30, 2024
StartActual
Feb 2, 2024
Primary completionActual
Apr 27, 2025
CompletionActual
Apr 27, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06230588
Responsible party
Sponsor
First posted
Jan 30, 2024
Start date
Feb 2, 2024
Primary completion
Apr 27, 2025
Completion
Apr 27, 2025
Last update
Jul 16, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH3906

Start the discussion